Maurizio Balestrino

Dr. Maurizio Balestrino

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child health (DINOGMI), University of Genoa, Italy.
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1999 in Brain Research
Verified
Journal Article
Closed access
MBMaurizio Balestrino
Maurizio Balestrino
JYJacob Young
Jacob Young
PAPeter Aitken
Peter Aitken

1 October 1986 in Brain Research
Verified
Journal Article
Closed access
MBMaurizio Balestrino
Maurizio Balestrino
GSGeorge G. Somjen
George G. Somjen

1 July 1986 in Brain Research
Verified
Journal Article
Closed access
MBMaurizio Balestrino
Maurizio Balestrino
PAPeter G. Aitken
Peter G. Aitken
GSGeorge G. Somjen
George G. Somjen

1 June 1995 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
MBMaurizio Balestrino
Maurizio Balestrino

7 April 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MBMaurizio Balestrino
Maurizio Balestrino
Creatine is a key player in heart contraction and energy metabolism. Creatine supplementation (throughout the paper, only supplementation with creatine monohydrate will be reviewed, as this is by far the most used and best-known way of supplementing creatine) increases creatine content even in the normal heart, and it is generally safe. In heart failure, creatine and phosphocreatine decrease because of decreased expression of the creatine transporter, and because phosphocreatine degrades to prevent adenosine triphosphate (ATP) exhaustion. This causes decreased contractility reserve of the myocardium and correlates with left ventricular ejection fraction, and it is a predictor of mortality. Thus, there is a strong rationale to supplement with creatine the failing heart. Pending additional trials, creatine supplementation in heart failure may be useful given data showing its effectiveness (1) against specific parameters of heart failure, and (2) against the decrease in muscle strength and endurance of heart failure patients. In heart ischemia, the majority of trials used phosphocreatine, whose mechanism of action is mostly unrelated to changes in the ergogenic creatine-phosphocreatine system. Nevertheless, preliminary data with creatine supplementation are encouraging, and warrant additional studies. Prevention of cardiac toxicity of the chemotherapy compounds anthracyclines is a novel field where creatine supplementation may also be useful. Creatine effectiveness in this case may be because anthracyclines reduce expression of the creatine transporter, and because of the pleiotropic antioxidant properties of creatine. Moreover, creatine may also reduce concomitant muscle damage by anthracyclines.

23 April 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
MBMaurizio Balestrino
Maurizio Balestrino
EAEnrico Adriano
Enrico Adriano